Pharmaceuticals News and Research

RSS

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

BioSante Pharmaceuticals, Inc., today announced additional positive safety data in its ongoing LibiGel Phase III clinical development program. For the second time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review, the DMC once again unanimously recommended continuation of the study as described in the FDA-agreed LibiGel safety study protocol, with no modifications.

22 Feb 2010

Insurers rebut criticisms of profits, rates

As the Obama Administration seizes on a proposed 39-percent rate hike by a California insurer earlier this month to rally new support for a health overhaul, that insurer's top executive is preparing to go before Congress, The Associated Press/Los Angeles Times reports.

22 Feb 2010

Boehringer Ingelheim Pharmaceuticals receives FDA approval for Mirapex ER in treatment of early PD

Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER® (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early idiopathic Parkinson's disease (PD). MIRAPEX ER is not indicated in advanced PD. Parkinson's disease is a chronic, slowly progressive and potentially debilitating neurological condition affecting nearly one million people in the U.S., with one person newly diagnosed every nine minutes.

22 Feb 2010

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a Phase IIb trial in adult lung transplant patients with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. RSV infection in lung transplant patients represents an important unmet medical need; the condition is associated with significant morbidity, including the development of acute lung transplant rejection in 10% to 20% of infected patients.

22 Feb 2010

Shire reports total revenues of $3,008 million for 2009

Shire plc the global specialty biopharmaceutical company, announces results for the year to December 31, 2009.

22 Feb 2010

WuXi PharmaTech's Suzhou non-clinical safety testing facility receives AAALAC accreditation

WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that its Suzhou non-clinical safety testing facility received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC). As a result of an extensive on-site evaluation, AAALAC determined that WuXi PharmaTech's facility meets the highest standards of animal care and research practices.

22 Feb 2010

Genetics associated with DILI and SSR: FDA and SAEC complete third release of data

The U.S. Food and Drug Administration and the International Serious Adverse Event Consortium (SAEC) today announced the third release of data on the genetic basis of drug-induced liver injury (DILI) and serious skin reactions (SSRs).

22 Feb 2010

IMS Health anticipates closing of merger by end of February 2010

IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced that it expects to close the merger providing for its acquisition by entities created by certain affiliates of TPG Capital, L.P. and the CPP Investment Board by the end of February 2010.

22 Feb 2010

As health insurance premiums rise sharply, lawmakers and consumers face tough choices

Steep increases in individual health insurance premiums are sparking reactions across the country.

21 Feb 2010

El Tejano Magazine article: Medical innovation and research help many Americans live longer, healthier

An article that recently appeared in El Tejano Magazine highlighted the fact that many Americans are living longer, healthier and more productive lives because of medical innovation and research.

20 Feb 2010

Research Roundup: Financing boomers' care; California's budget cuts; Racial disparities in surgical outcomes

Health Affairs: Chronic Conditions Account For Rise In Medicare Spending From 1987 To 2006 - "Medicare beneficiaries' medical needs, and where beneficiaries undergo treatment, have changed dramatically over the past two decades." For example, the authors write, "heart disease ranked first among the top-ten conditions in terms of attributable share of growth from 1987 to 1997, accounting for nearly 14 percent of the increase in Medicare spending."

20 Feb 2010

China Qinba Pharmaceuticals merges with Allstar Restaurants

Allstar Restaurants, today announced that effective on February 12, 2010, the Company’s wholly-owned subsidiary merged with China Qinba Pharmaceuticals, Inc.

20 Feb 2010

First hands-on workshop on E-beam and X-ray Irradiation Technologies

The National Center for Electron Beam Research, located on the campus of Texas A&M University, will conduct a week-long, hands-on workshop in E-Beam and X-ray Irradiation Technologies April 4-8.

19 Feb 2010

Aeolus Pharmaceuticals' first fiscal quarter net loss rises

Aeolus Pharmaceuticals, Inc. announced today financial results for the three months ended December 31, 2009. The Company reported a net loss of $15,276,000, or $0.33 per basic share, compared to a loss of $459,000, or $0.01 per basic share, for the three months ended December 31, 2008.

19 Feb 2010

Polyphor discovers new class of antibiotics effective against multi-drug resistant Gram-negative bacteria

Today, Polyphor Ltd published the discovery of a new class of antibiotics with a novel mode of action (Science, VOL 327, ISSUE 5968). This proprietary new class of antibiotics is effective against multi-drug resistant Gram-negative bacteria, opening up new treatment options for serious and often life-threatening infections. The most advanced drug candidate in this new class, POL7080, selectively kills the dangerous bacteria Pseudomonas aeruginosa.

19 Feb 2010

Rib-X Pharmaceuticals co-founder discovers new ribosomal structures of antibiotics

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, and Yale University today announced the discovery by Thomas Steitz, Ph.D., co-founder of Rib-X and Yale University professor, of important new ribosomal structures of antibiotics, enabling the potential creation of novel treatments for drug resistant infections, including resistant tuberculosis (TB).

19 Feb 2010

Micro Imaging Technology becomes Micro Identification Technologies

Micro Imaging Technology, Inc. today announced that it has changed is company name to Micro Identification Technologies to better reflect the extensive capabilities of its ID technology software.

19 Feb 2010

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

Depomed, Inc. today announced that it has received final meeting minutes from the FDA for a pre-NDA meeting related to DM-1796 for postherpetic neuralgia (PHN) held in December 2009. Depomed also commented on recent public disclosures related to the Complete Response letter from the U.S. Food and Drug Administration regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets.

19 Feb 2010

Sepracor to merge with Dainippon Sumitomo Pharma America

Sepracor Inc. and Dainippon Sumitomo Pharma Co., Ltd. (DSP) today announce the resignation of Adrian Adams as President and Chief Executive Officer and Director of Sepracor and as Executive Officer of DSP, effective immediately, and the appointment of Saburo Hamanaka as Chairman of Sepracor and Executive Officer of DSP. Sepracor and DSP also announce the planned merger of Sepracor and DSP’s subsidiary, Dainippon Sumitomo Pharma America, Inc. (DSPA), to be completed on April 1, 2010, with Sepracor as the surviving company.

19 Feb 2010

Delay in Vibativ's approval for nosocomial pneumonia to reduce previously forecasted commercial impact

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that delays in the U.S. approval and launch of Theravance/Astellas's Vibativ (telavancin) for the treatment of nosocomial pneumonia will reduce by more than half the commercial impact that it was previously forecasted to garner in the methicillin-resistant Staphylococcus aureus (MRSA) drug market.

19 Feb 2010

Pharmaceuticals News and Research

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

Insurers rebut criticisms of profits, rates

Boehringer Ingelheim Pharmaceuticals receives FDA approval for Mirapex ER in treatment of early PD

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

Shire reports total revenues of $3,008 million for 2009

WuXi PharmaTech's Suzhou non-clinical safety testing facility receives AAALAC accreditation

Genetics associated with DILI and SSR: FDA and SAEC complete third release of data

IMS Health anticipates closing of merger by end of February 2010

As health insurance premiums rise sharply, lawmakers and consumers face tough choices

El Tejano Magazine article: Medical innovation and research help many Americans live longer, healthier

Research Roundup: Financing boomers' care; California's budget cuts; Racial disparities in surgical outcomes

China Qinba Pharmaceuticals merges with Allstar Restaurants

First hands-on workshop on E-beam and X-ray Irradiation Technologies

Aeolus Pharmaceuticals' first fiscal quarter net loss rises

Polyphor discovers new class of antibiotics effective against multi-drug resistant Gram-negative bacteria

Rib-X Pharmaceuticals co-founder discovers new ribosomal structures of antibiotics

Micro Imaging Technology becomes Micro Identification Technologies

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

Sepracor to merge with Dainippon Sumitomo Pharma America

Delay in Vibativ's approval for nosocomial pneumonia to reduce previously forecasted commercial impact

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence